Accordingly, the CheckMate 227 study demonstrated survival improvement with dual inhibition of PD‐1 (nivolumab) and cytotoxic T lymphocyte antigen 4 (CTLA‐4) (ipilimumab) in patients with advanced NSCLC and PD‐L1 TPS of ≥1%, as compared with chemotherapy.4 Here, PDCD1 is linked to non-small cell lung carcinoma.